Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.

Diebold M, Fischer-Barnicol B, Tsagkas C, Kuhle J, Kappos L, Derfuss T, Décard BF.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 11;6(5). pii: e594. doi: 10.1212/NXI.0000000000000594. Print 2019 Sep.

2.

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.

Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T.

Mult Scler Relat Disord. 2018 Oct;25:14-20. doi: 10.1016/j.msard.2018.07.005. Epub 2018 Jul 6.

3.

Characterization of social cognition impairment in multiple sclerosis.

Neuhaus M, Bagutti S, Yaldizli Ö, Zwahlen D, Schaub S, Frey B, Fischer-Barnicol B, Burgunder JM, Martory MD, Pöttgen J, Annoni JM, Penner IK.

Eur J Neurol. 2018 Jan;25(1):90-96. doi: 10.1111/ene.13457. Epub 2017 Oct 24.

PMID:
28898535
4.

T-cell response against varicella-zoster virus in fingolimod-treated MS patients.

Ricklin ME, Lorscheider J, Waschbisch A, Paroz C, Mehta SK, Pierson DL, Kuhle J, Fischer-Barnicol B, Sprenger T, Lindberg RL, Kappos L, Derfuss T.

Neurology. 2013 Jul 9;81(2):174-81. doi: 10.1212/WNL.0b013e31829a3311. Epub 2013 May 22.

PMID:
23700335

Supplemental Content

Loading ...
Support Center